{
  "fullName": "S. H. Advani",
  "slug": "s-h-advani",
  "title": "MD",
  "specialty": "Medicine",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 27.94,
  "hIndex": 99,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Kiara Advani, , is an Indian actress who works primarily in Hindi films. One of the highest-paid actresses in India, Advani is a recipient of several accolades including an IIFA Award and two Zee Cine Awards, alongside nominations for two Filmfare Awards.",
  "aiSummary": "S. H. Advani is a medicine specialist with an H-index of 99 at Hemato-oncology pioneer (Member). Has been published in New England Journal of Medicine, Nature Medicine, The Lancet. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Hemato-oncology pioneer"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Hemato-oncology pioneer",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Medicine"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "The 2016 revision of the World Health Organization classification of lymphoid neoplasms",
      "journal": "Blood",
      "year": 2016,
      "citationCount": 7633,
      "doi": "10.1182/blood-2016-01-643569",
      "sourceUrl": "https://doi.org/10.1182/blood-2016-01-643569",
      "verified": true
    },
    {
      "title": "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma",
      "journal": "New England Journal of Medicine",
      "year": 2013,
      "citationCount": 1657,
      "doi": "10.1056/nejmoa1306220",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1306220",
      "verified": true
    },
    {
      "title": "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee",
      "journal": "Blood",
      "year": 2022,
      "citationCount": 1340,
      "doi": "10.1182/blood.2022015851",
      "sourceUrl": "https://doi.org/10.1182/blood.2022015851",
      "verified": true
    },
    {
      "title": "Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 1107,
      "doi": "10.1200/jco.2012.42.7906",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.42.7906",
      "verified": true
    },
    {
      "title": "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma",
      "journal": "Nature Medicine",
      "year": 2015,
      "citationCount": 1096,
      "doi": "10.1038/nm.3884",
      "sourceUrl": "https://doi.org/10.1038/nm.3884",
      "verified": true
    },
    {
      "title": "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma",
      "journal": "New England Journal of Medicine",
      "year": 2018,
      "citationCount": 1071,
      "doi": "10.1056/nejmoa1807315",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1807315",
      "verified": true
    },
    {
      "title": "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 978,
      "doi": "10.1200/jco.2011.38.0402",
      "sourceUrl": "https://doi.org/10.1200/jco.2011.38.0402",
      "verified": true
    },
    {
      "title": "Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia",
      "journal": "New England Journal of Medicine",
      "year": 2015,
      "citationCount": 913,
      "doi": "10.1056/nejmoa1501548",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1501548",
      "verified": true
    },
    {
      "title": "<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome",
      "journal": "Journal of Clinical Oncology",
      "year": 2016,
      "citationCount": 780,
      "doi": "10.1200/jco.2016.66.4482",
      "sourceUrl": "https://doi.org/10.1200/jco.2016.66.4482",
      "verified": true
    },
    {
      "title": "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial",
      "journal": "The Lancet",
      "year": 2018,
      "citationCount": 704,
      "doi": "10.1016/s0140-6736(18)32984-2",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(18)32984-2",
      "verified": true
    },
    {
      "title": "Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma",
      "journal": "New England Journal of Medicine",
      "year": 2013,
      "citationCount": 551,
      "doi": "10.1056/nejmoa1214561",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1214561",
      "verified": true
    },
    {
      "title": "Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines",
      "journal": "PLoS ONE",
      "year": 2012,
      "citationCount": 526,
      "doi": "10.1371/journal.pone.0033788",
      "sourceUrl": "https://doi.org/10.1371/journal.pone.0033788",
      "verified": true
    },
    {
      "title": "Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy",
      "journal": "Blood",
      "year": 2016,
      "citationCount": 482,
      "doi": "10.1182/blood-2016-05-718528",
      "sourceUrl": "https://doi.org/10.1182/blood-2016-05-718528",
      "verified": true
    },
    {
      "title": "In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2010,
      "citationCount": 481,
      "doi": "10.1200/jco.2010.28.9793",
      "sourceUrl": "https://doi.org/10.1200/jco.2010.28.9793",
      "verified": true
    },
    {
      "title": "Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma",
      "journal": "Journal of Clinical Oncology",
      "year": 2018,
      "citationCount": 469,
      "doi": "10.1200/jco.2018.78.5246",
      "sourceUrl": "https://doi.org/10.1200/jco.2018.78.5246",
      "verified": true
    },
    {
      "title": "Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA",
      "journal": "Science Translational Medicine",
      "year": 2016,
      "citationCount": 467,
      "doi": "10.1126/scitranslmed.aai8545",
      "sourceUrl": "https://doi.org/10.1126/scitranslmed.aai8545",
      "verified": true
    },
    {
      "title": "Non-Hodgkin's Lymphomas",
      "journal": "Journal of the National Comprehensive Cancer Network",
      "year": 2011,
      "citationCount": 457,
      "doi": "10.6004/jnccn.2011.0046",
      "sourceUrl": "https://doi.org/10.6004/jnccn.2011.0046",
      "verified": true
    },
    {
      "title": "Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results",
      "journal": "Blood",
      "year": 2015,
      "citationCount": 396,
      "doi": "10.1182/blood-2015-03-635326",
      "sourceUrl": "https://doi.org/10.1182/blood-2015-03-635326",
      "verified": true
    },
    {
      "title": "A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis",
      "journal": "The Lancet Oncology",
      "year": 2016,
      "citationCount": 375,
      "doi": "10.1016/s1470-2045(15)00533-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(15)00533-1",
      "verified": true
    },
    {
      "title": "International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)",
      "journal": "Annals of Oncology",
      "year": 2017,
      "citationCount": 366,
      "doi": "10.1093/annonc/mdx097",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdx097",
      "verified": true
    },
    {
      "title": "Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin",
      "journal": "Blood",
      "year": 2014,
      "citationCount": 348,
      "doi": "10.1182/blood-2013-12-542142",
      "sourceUrl": "https://doi.org/10.1182/blood-2013-12-542142",
      "verified": true
    },
    {
      "title": "Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing",
      "journal": "Blood",
      "year": 2015,
      "citationCount": 335,
      "doi": "10.1182/blood-2015-03-635169",
      "sourceUrl": "https://doi.org/10.1182/blood-2015-03-635169",
      "verified": true
    },
    {
      "title": "Non-Hodgkin’s Lymphomas",
      "journal": "Journal of the National Comprehensive Cancer Network",
      "year": 2010,
      "citationCount": 328,
      "doi": "10.6004/jnccn.2010.0021",
      "sourceUrl": "https://doi.org/10.6004/jnccn.2010.0021",
      "verified": true
    },
    {
      "title": "Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study",
      "journal": "The Lancet Oncology",
      "year": 2015,
      "citationCount": 326,
      "doi": "10.1016/s1470-2045(15)70128-2",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(15)70128-2",
      "verified": true
    },
    {
      "title": "Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma",
      "journal": "Blood",
      "year": 2017,
      "citationCount": 317,
      "doi": "10.1182/blood-2017-10-811224",
      "sourceUrl": "https://doi.org/10.1182/blood-2017-10-811224",
      "verified": true
    },
    {
      "title": "Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 303,
      "doi": "10.1200/jco.2012.43.4803",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.43.4803",
      "verified": true
    },
    {
      "title": "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression",
      "journal": "Blood",
      "year": 2015,
      "citationCount": 297,
      "doi": "10.1182/blood-2014-09-598763",
      "sourceUrl": "https://doi.org/10.1182/blood-2014-09-598763",
      "verified": true
    },
    {
      "title": "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma",
      "journal": "New England Journal of Medicine",
      "year": 2022,
      "citationCount": 293,
      "doi": "10.1056/nejmoa2206125",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2206125",
      "verified": true
    },
    {
      "title": "The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma",
      "journal": "Cancer Cell",
      "year": 2021,
      "citationCount": 284,
      "doi": "10.1016/j.ccell.2021.08.011",
      "sourceUrl": "https://doi.org/10.1016/j.ccell.2021.08.011",
      "verified": true
    },
    {
      "title": "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project",
      "journal": "Journal of Clinical Oncology",
      "year": 2015,
      "citationCount": 277,
      "doi": "10.1200/jco.2014.60.3969",
      "sourceUrl": "https://doi.org/10.1200/jco.2014.60.3969",
      "verified": true
    },
    {
      "title": "Postibrutinib outcomes in patients with mantle cell lymphoma",
      "journal": "Blood",
      "year": 2016,
      "citationCount": 275,
      "doi": "10.1182/blood-2015-10-673145",
      "sourceUrl": "https://doi.org/10.1182/blood-2015-10-673145",
      "verified": true
    },
    {
      "title": "Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience",
      "journal": "Blood",
      "year": 2013,
      "citationCount": 258,
      "doi": "10.1182/blood-2013-03-491514",
      "sourceUrl": "https://doi.org/10.1182/blood-2013-03-491514",
      "verified": true
    },
    {
      "title": "Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma",
      "journal": "Blood",
      "year": 2018,
      "citationCount": 246,
      "doi": "10.1182/blood-2017-11-815183",
      "sourceUrl": "https://doi.org/10.1182/blood-2017-11-815183",
      "verified": true
    },
    {
      "title": "Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)",
      "journal": "The Lancet Haematology",
      "year": 2019,
      "citationCount": 243,
      "doi": "10.1016/s2352-3026(19)30026-2",
      "sourceUrl": "https://doi.org/10.1016/s2352-3026(19)30026-2",
      "verified": true
    },
    {
      "title": "Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium",
      "journal": "Journal of Clinical Oncology",
      "year": 2019,
      "citationCount": 241,
      "doi": "10.1200/jco.19.00743",
      "sourceUrl": "https://doi.org/10.1200/jco.19.00743",
      "verified": true
    },
    {
      "title": "The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma",
      "journal": "Annals of Oncology",
      "year": 2021,
      "citationCount": 239,
      "doi": "10.1016/j.annonc.2021.12.002",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2021.12.002",
      "verified": true
    },
    {
      "title": "Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma",
      "journal": "Blood",
      "year": 2017,
      "citationCount": 235,
      "doi": "10.1182/blood-2017-05-780049",
      "sourceUrl": "https://doi.org/10.1182/blood-2017-05-780049",
      "verified": true
    },
    {
      "title": "Stage I and II Follicular Non-Hodgkin’s Lymphoma: Long-Term Follow-Up of No Initial Therapy",
      "journal": "Journal of Clinical Oncology",
      "year": 2004,
      "citationCount": 233,
      "doi": "10.1200/jco.2004.10.086",
      "sourceUrl": "https://doi.org/10.1200/jco.2004.10.086",
      "verified": true
    },
    {
      "title": "Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)",
      "journal": "Journal of Clinical Oncology",
      "year": 2004,
      "citationCount": 232,
      "doi": "10.1200/jco.2004.07.048",
      "sourceUrl": "https://doi.org/10.1200/jco.2004.07.048",
      "verified": true
    },
    {
      "title": "A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies",
      "journal": "Clinical Cancer Research",
      "year": 2011,
      "citationCount": 213,
      "doi": "10.1158/1078-0432.ccr-11-1425",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-11-1425",
      "verified": true
    },
    {
      "title": "In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study",
      "journal": "Blood",
      "year": 2011,
      "citationCount": 211,
      "doi": "10.1182/blood-2011-05-355222",
      "sourceUrl": "https://doi.org/10.1182/blood-2011-05-355222",
      "verified": true
    },
    {
      "title": "Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial",
      "journal": "Blood",
      "year": 2012,
      "citationCount": 208,
      "doi": "10.1182/blood-2012-04-421057",
      "sourceUrl": "https://doi.org/10.1182/blood-2012-04-421057",
      "verified": true
    },
    {
      "title": "Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment",
      "journal": "Blood",
      "year": 2011,
      "citationCount": 204,
      "doi": "10.1182/blood-2011-03-345272",
      "sourceUrl": "https://doi.org/10.1182/blood-2011-03-345272",
      "verified": true
    },
    {
      "title": "Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results",
      "journal": "Blood",
      "year": 2021,
      "citationCount": 197,
      "doi": "10.1182/blood.2020009178",
      "sourceUrl": "https://doi.org/10.1182/blood.2020009178",
      "verified": true
    },
    {
      "title": "Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 194,
      "doi": "10.1200/jco.2012.43.4589",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.43.4589",
      "verified": true
    },
    {
      "title": "Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248",
      "journal": "Clinical Cancer Research",
      "year": 2007,
      "citationCount": 189,
      "doi": "10.1158/1078-0432.ccr-06-2511",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-06-2511",
      "verified": true
    },
    {
      "title": "Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 187,
      "doi": "10.1200/jco.2008.21.3017",
      "sourceUrl": "https://doi.org/10.1200/jco.2008.21.3017",
      "verified": true
    },
    {
      "title": "A Phase <scp>II</scp> trial of Belinostat ( <scp>PXD</scp> 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma",
      "journal": "British Journal of Haematology",
      "year": 2014,
      "citationCount": 187,
      "doi": "10.1111/bjh.13222",
      "sourceUrl": "https://doi.org/10.1111/bjh.13222",
      "verified": true
    },
    {
      "title": "NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019",
      "journal": "Journal of the National Comprehensive Cancer Network",
      "year": 2019,
      "citationCount": 186,
      "doi": "10.6004/jnccn.2019.0029",
      "sourceUrl": "https://doi.org/10.6004/jnccn.2019.0029",
      "verified": true
    },
    {
      "title": "Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status",
      "journal": "Cancer Immunology Research",
      "year": 2016,
      "citationCount": 183,
      "doi": "10.1158/2326-6066.cir-16-0201",
      "sourceUrl": "https://doi.org/10.1158/2326-6066.cir-16-0201",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5060314041",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/d/d4/Kiara_Advani_snapped_at_the_screening_of_Shershaah_%28cropped%29.jpg/330px-Kiara_Advani_snapped_at_the_screening_of_Shershaah_%28cropped%29.jpg"
}